Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases
Retrieved on:
Wednesday, June 7, 2023
Modulation, Therapy, Investment, Sofinnova, ARCH Venture Partners, Doctor of Philosophy, Lightspeed Venture Partners, Science, Mozart and smallpox, Bayer, Eli Lilly and Company, Partner, Patient, Growth, Merck, Merck & Co., IND, Autoimmunity, Inflammation, Pharmaceutical industry, Vaccine, Wolfgang Amadeus Mozart
SEATTLE, June 7, 2023 /PRNewswire/ -- Mozart Therapeutics, a leading developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory diseases, today announced it has raised $25 million from new investors in a Series A extension, bringing the total raise to $80 million. The proceeds will be used to advance the company's lead candidate, MTX-101, into first-in-human clinical trials and to support pipeline expansion.
Key Points:
- The proceeds will be used to advance the company's lead candidate, MTX-101, into first-in-human clinical trials and to support pipeline expansion.
- New investors Pfizer Ventures, AbbVie Ventures, Ono Venture Investment and UPMC Enterprises participated in the round.
- Mozart is developing a portfolio of CD8 Treg Modulators including MTX-101, a bispecific autoimmune checkpoint inhibitor, for the treatment of autoimmune diseases.
- "We look forward to the company's emerging data demonstrating the promise to bring forward novel CD8 Treg modulators with broad therapeutic potential."